PBAC's latest decision on Calcipotriol with betamethasone dipropionate: Recommended (2025). Considered for Treatment of chronic stable plaque type psoriasis vulgaris, specifically for scalp psoriasis and mild to moderate plaque psoriasis on the body in adults where the condition is inadequately controlled by potent topical corticosteroid monotherapy.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2016
Submissions
5
2016 → 2025
Eligible population
Adults with chronic stable plaque type psoriasis vulgaris on the scalp and body, inadequately controlled by potent topical corticosteroid monotherapy.
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
ORR
Key trials
Trial 0155/2018
Comparator
calcipotriol + betamethasone ointment
Economic model
Cost-minimisation
Budget impact
$10M
ICER note
Cost-minimisation analysis; no ICER calculated as equi-effective doses were assumed based on bioequivalence determination.
Submission history
Nov 2016: Recommended with restriction · Restricted
Mar 2018: Not recommended · Restricted
Jul 2023: Recommended with restriction · Authority Required
Jul 2025: Recommended with restriction · Restricted